Fasano M - Search Results

1

Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease.

Alberio T, Pippione AC, Comi C, Olgiati S, Cecconi D, Zibetti M, Lopiano L, Fasano M. Alberio T, et al. Among authors: fasano m. IUBMB Life. 2012 Oct;64(10):846-52. doi: 10.1002/iub.1073. Epub 2012 Jul 20. IUBMB Life. 2012. PMID: 22815142 Free article.

2

Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients.

Lopiano L, Chiesa M, Digilio G, Giraudo S, Bergamasco B, Torre E, Fasano M. Lopiano L, et al. Among authors: fasano m. Biochim Biophys Acta. 2000 Mar 17;1500(3):306-12. doi: 10.1016/s0925-4439(99)00116-7. Biochim Biophys Acta. 2000. PMID: 10699372 Free article.

3

Nuclear magnetic relaxation dispersion profiles of substantia nigra pars compacta in Parkinson's disease patients are consistent with protein aggregation.

Lopiano L, Fasano M, Giraudo S, Digilio G, Koenig SH, Torre E, Bergamasco B, Aime S. Lopiano L, et al. Among authors: fasano m. Neurochem Int. 2000 Oct;37(4):331-6. doi: 10.1016/s0197-0186(00)00036-x. Neurochem Int. 2000. PMID: 10825573

4

Isolation and 13C-NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson's disease.

Aime S, Bergamasco B, Casu M, Digilio G, Fasano M, Giraudo S, Lopiano L. Aime S, et al. Among authors: fasano m. Mov Disord. 2000 Sep;15(5):977-81. doi: 10.1002/1531-8257(200009)15:5<977::aid-mds1032>3.0.co;2-q. Mov Disord. 2000. PMID: 11009208

5

Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein.

Fasano M, Giraudo S, Coha S, Bergamasco B, Lopiano L. Fasano M, et al. Neurochem Int. 2003 Jun;42(7):603-6. doi: 10.1016/s0197-0186(02)00161-4. Neurochem Int. 2003. PMID: 12590943

6

Proteome analysis of mesencephalic tissues: evidence for Parkinson's disease.

Basso M, Giraudo S, Lopiano L, Bergamasco B, Bosticco E, Cinquepalmi A, Fasano M. Basso M, et al. Among authors: fasano m. Neurol Sci. 2003 Oct;24(3):155-6. doi: 10.1007/s10072-003-0106-2. Neurol Sci. 2003. PMID: 14598063

7

Proteome analysis of human substantia nigra in Parkinson's disease.

Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Basso M, et al. Among authors: fasano m. Proteomics. 2004 Dec;4(12):3943-52. doi: 10.1002/pmic.200400848. Proteomics. 2004. PMID: 15526345

8

Modifications of the iron-neuromelanin system in Parkinson's disease.

Fasano M, Bergamasco B, Lopiano L. Fasano M, et al. J Neurochem. 2006 Feb;96(4):909-16. doi: 10.1111/j.1471-4159.2005.03638.x. Epub 2006 Jan 17. J Neurochem. 2006. PMID: 16417570 Free article. Review.

9

Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies.

Fasano M, Bergamasco B, Lopiano L. Fasano M, et al. J Neural Transm (Vienna). 2006 Jun;113(6):769-74. doi: 10.1007/s00702-005-0448-4. Epub 2006 May 12. J Neural Transm (Vienna). 2006. PMID: 16755381 Review.

10

alpha-Synuclein protects SH-SY5Y cells from dopamine toxicity.

Colapinto M, Mila S, Giraudo S, Stefanazzi P, Molteni M, Rossetti C, Bergamasco B, Lopiano L, Fasano M. Colapinto M, et al. Among authors: fasano m. Biochem Biophys Res Commun. 2006 Nov 3;349(4):1294-300. doi: 10.1016/j.bbrc.2006.08.163. Epub 2006 Sep 5. Biochem Biophys Res Commun. 2006. PMID: 16978583

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

505 results

Search Page

Filters